The testosterone replacement therapy market is projected to grow from $1.75B in 2022 to $1.85B in 2023, with a compound annual growth rate (CAGR) of 5.4%. Furthermore, the market is expected to reach $2.22B by 2027, with a CAGR of 4.6%, according to a report from Research & Markets.
Testosterone replacement therapy uses hormones to treat low testosterone (T) levels in males, which can occur due to aging or a medical condition.
The main types of testosterone replacement therapy include oral, implants, gel or creams, patches, buccal adhesive, parenteral, and others. Oral administration involves taking substances through the mouth, such as tablets, capsules, and syrups. Major indications for low testosterone are hypogonadism, autoimmune conditions, genetic disorders, sex organ surgeries, and others, treated with various active ingredients such as testosterone, methyl testosterone, testosterone undecanoate, testosterone enanthate, and testosterone cypionate, used by end users like hospitals, clinics, and others.